Table 1.

Demographic and clinical characteristics of patients with Peutz-Jeghers syndrome (n = 96)

Characteristic	Value
Age at the end of follow-up, yr	34.7 (10.5–81.2)
Follow-up duration, yr	6.2 (0–22.5)
Age of PJS diagnosis, yr	23.4 (0.9–72.4)
< 10	11 (11.5)
10–20	29 (30.2)
20–30	14 (14.6)
30–40	20 (20.8)
40–50	9 (9.4)
50–60	8 (8.3)
60–70	4 (4.2)
> 70	1 (1.0)
Sex
Male	48 (50.0)
Female	48 (50.0)
Family history of PJS
Positive	22 (22.9)
Negative	43 (44.8)
Unknown	31 (32.3)
STK11 mutation
Positive	25 (26.0)
Negative	14 (14.6)
Unchecked	57 (59.4)
Cancer	21 (21.9)
Age of cancer diagnosis, yr	42.5 (15.5–59.7)
GI cancer	10 (10.4)
Age of GI cancer diagnosis, yr	48.6 (16.2–66.6)
Extra-GI cancer	13 (13.5)
Age of extra-GI cancer diagnosis, yr	38.0 (15.5–59.7)

Values are presented as median (range) or number (%).

PJS, Peutz-Jeghers syndrome; STK11, serine/threonine kinase 11; GI, gastrointestinal.